Skip to content
Clinical Trials – home
RomaniaBack to Romania

Clinical trials in Rosu – page 13

227 clinical trials in Rosu, Romania. Every trial is listed in the EU Clinical Trials Register and updated daily.

RomaniaOur site in RomaniaStudii.Clinice.ro(opens in a new tab)
Rosu at a glance
227
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

227 trials in Rosu

Open in trial search

Dermatitis atopic

Not recruiting

Study on Tralokinumab and Topical Corticosteroids for Children and Infants with Moderate-to-Severe Atopic Dermatitis

Registered drug
Countries:RomaniaRomania
  • Participants:0–17 years
  • Substances:Tralokinumab
  • Sponsor:Leo Pharma A/S
Countries:RomaniaRomania
  • Participants:18–64 years · Healthy volunteers
  • Substances:Nitrofurantoin
  • Sponsor:Antibiotice S.A.

Study of blinatumomab and a drug combination for older adults with newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Asparaginase
  • Sponsor:Amgen Inc.

Efficacy and Safety Evaluation of Litifilimab in Adults with Active Systemic Lupus Erythematosus on Standard Nonbiologic Lupus Care: A Phase 3 Randomized Controlled Trial

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Litifilimab
  • Sponsor:Biogen Idec Research Limited
Countries:RomaniaRomania
  • Participants:18–64 years · Healthy volunteers
  • Substances:Cefixime
  • Sponsor:Antibiotice S.A.

Endometriosis

Not recruiting

A study testing vipoglanstat for women with moderate to severe endometriosis-related pain

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years
  • Substances:Vipoglanstat
  • Sponsor:Gesynta Pharma AB

Chronic kidney disease+1

Not recruiting

A study of ziltivekimab compared to placebo in people with heart and blood vessel disease, chronic kidney disease and inflammation

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Breast cancer+1

Not recruiting

Study of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Cholangiocarcinoma+7

Not recruiting

Study of bemarituzumab treatment for patients with solid tumors that have high levels of FGFR2b protein

InvestigationalNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Bemarituzumab
  • Sponsor:Amgen Inc.

Study of subcutaneous nivolumab with ipilimumab and chemotherapy in previously untreated patients with metastatic or recurrent non-small cell lung cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study of tarlatamab with durvalumab, carboplatin and etoposide versus standard treatment in patients with previously untreated extensive stage small cell lung cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Amgen Inc.

Adenocarcinoma gastric+3

Not recruiting

Study of zolbetuximab, pembrolizumab and chemotherapy in adults with HER2-negative, Claudin 18.

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Astellas Pharma Global Development Inc.

Other cities in Romania

The busiest research cities in the country

All 63 cities in Romania

Clinical research in Rosu

What the registry says about research in the country

01 Cardiovascular Disease – Atrial Fibrillation

Research in Rosu is centered on a common heart rhythm disorder that raises the chance of serious vascular events.

  • Evaluation of REGN7508 compared with standard anticoagulant therapy
  • Combined REGN7508 and REGN9933 versus placebo
  • Risk assessment of clinically relevant bleeding
  • Stroke and systemic embolism prevention for patients unsuitable for oral anticoagulation

The trials aim to expand treatment choices and lower the incidence of stroke and embolic complications in atrial fibrillation.

02 Anticoagulation Safety in Atrial Fibrillation

Ongoing studies examine how to protect patients from ischemic stroke while reducing the likelihood of major bleeding events.

  • Comparison of bleeding risk between experimental agents and apixaban
  • Evaluation of major bleeding outcomes with dual‑target therapy
  • Analysis of stroke prevention effectiveness in high‑risk cohorts
  • Safety profiling for participants unable to use conventional oral anticoagulants

Findings are expected to inform safer anticoagulation strategies for individuals living with atrial fibrillation.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.